Search PubMed⌕ Search

PubMed · 12048620

[The epilepsypsychoses].

Abstract

The association of epilepsy, the epilepsypsychoses and schizophrenia has attracted the attention of psychiatrists and neurologists since the nineteenth century. While until the 1970ies German speaking psychiatry had shown great interest, in recent years there have been only a small number of publications on this topic. However there has been intensive research likewise on the epilepsypsychoses, especially on the association of temporal lobe epilepsy and schizophrenia in the English-speaking psychiatry. The epilepsypsychoses are inadequately categorized by the modern classification systems. Current knowledge of either the epilepsypsychoses or the relationship between epilepsy and schizophrenia is examined.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Ch Prüter, B Pohlmann-Eden. 2002. [The epilepsypsychoses].. https://doi.org/10.1055/s-2002-32024

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Long-term seizure outcomes and factors associated with response to adjunctive everolimus in TSC-associated epilepsy.

BACKGROUND: Everolimus, a mechanistic target of rapamycin (mTOR) inhibitor, is increasingly used in tuberous sclerosis complex (TSC)-associated epilepsy; however, long-term real-world outcomes and factors associated with favorable response remain unclear. This study aimed to evaluate the long-term seizure outcomes of adjunctive everolimus and explore clinical factors associated with treatment response. METHODS: We retrospectively recruited 21 patients with active TSC-associated epilepsy receiving adjunctive everolimus and assessed seizure outcomes during follow-up. Clinical characteristics were compared between responders and non-responders at 1 year after treatment initiation. RESULTS: Over a median treatment duration of 72 months, responder rates ranged from 53.8% to 64.7%, and seizure-free rates ranged from 33.3% to 41.2%. Responders had fewer involved organ systems at baseline (median 3 vs. 4, p = 0.020) and lower anti-seizure medication burden (median 2 vs. 4, p = 0.045). Younger age at treatment initiation showed a trend toward improved response. CONCLUSION: Adjunctive everolimus was associated with sustained long-term seizure reduction in this real-world cohort. In exploratory analyses, fewer involved organ systems and fewer baseline ASMs were associated with favorable treatment response. These findings require validation in larger prospective cohorts.

Epilepsy↗